Strong infusion growth, harder comps ahead
- Option Care Health sells infusion care in homes and alternate sites, a lower-cost setting than many hospital visits.
- Management says its national reach covers 96% of the U.S. population.
- Q2 2025 revenue grew 15.4%, with both acute and chronic therapies growing in the mid-teens.
- Full-year 2025 guidance rose to $5.5 billion to $5.65 billion of revenue and $465 million to $475 million of adjusted EBITDA.
- The STELARA reset is still a real drag, with about a $20 million Q2 gross profit hit and a full-year hit near the high end of $60 million to $70 million.
Execution is beating the drug hit
The bull case got stronger after Q2 2025. Option Care again posted mid-teens growth in both acute and chronic therapies. That matters because Q1 could have been a one-time boost from competitor disruption. Q2 showed the gains were broader and more durable.
Management also raised full-year 2025 guidance for revenue, adjusted EBITDA, and adjusted EPS. That raise came even after the company absorbed about a $20 million Q2 gross profit hit from STELARA and said the full-year STELARA impact should land near the high end of the prior $60 million to $70 million range. The message is simple: the rest of the portfolio is growing fast enough to cover a known drug economics problem.
The bear case has not disappeared. Acute growth is unusually strong for a mature part of the business, and the company will start facing harder comparisons as it laps the late-2024 period of competitor disruption. If acute growth slows, chronic therapies will need to carry more of the load. Finn's view stays mixed because the company is executing well now, but investors still need proof that this growth can hold into 2026.
Paid to move infusions out of hospitals
Option Care provides infusion care at home and in alternate sites. Patients receive complex drugs through an IV or similar method, but outside a hospital when clinically appropriate. The value pitch is lower cost for payers, more comfort for patients, and broad clinical reach for drug makers.
The company gets paid through reimbursement for the drug, clinical per diems, and nursing services. Its scale helps. Management says the network covers 96% of the U.S. population, with nearly 90 pharmacies and a large nursing network supporting care delivery.
This model can break when drug economics change faster than expected, when payers push back on rates, or when key supplies become scarce. STELARA is the current example of drug economics changing in a painful way. The IV solution shortage in 2024 showed how supply disruptions can limit new patient starts, even when demand is there.
A broad basket of infusion therapies
Acute infusion therapies
This includes mature therapies such as intravenous antibiotics and nutrition support. Growth was in the mid-teens in Q2 2025, helped by market share gains and shifting competitive dynamics.
Chronic infusion therapies
Chronic therapies are a major part of the business and also grew in the mid-teens in Q2 2025. These therapies often serve patients with long-term or complex conditions.
Rare, orphan, and limited distribution drugs
These newer therapies are a key growth driver. Examples in the internal portfolio include VYJUVEK, and management says this area benefits from national scale and pharma partnerships.
Biosimilar-exposed therapies
Some drugs can face pricing pressure when biosimilars enter the market. STELARA is the main current pressure point, while the portfolio also includes therapies facing biosimilar changes such as Remicade.
ALS and other specialty programs
The portfolio includes specialty therapies for conditions such as ALS, including RADICAVA. These programs can expand the clinical relationship with referral sources and payers.
Nursing network and infusion suites
The care model depends on nurses, pharmacies, and infusion suites, not only the drugs. In Q2 2025, management said about 35% of nursing visits occurred in company suites and Naven Health completed almost 54,000 nursing visits.
Chronic is the larger side
The mix uses management's Q2 and Q3 2024 commentary that chronic was roughly 75% of revenue and acute was roughly 25%. Q2 2025 management did not give a fresh mix, but said both acute and chronic therapies grew in the mid-teens.
What could go wrong
STELARA economics reset
High impact · High oddsThis is already happening. Management said the Q2 2025 gross profit hit was about $20 million and that the full-year 2025 impact should be near the high end of the $60 million to $70 million range. The company raised guidance anyway, but this is still a real margin drag.
Acute growth fades after hard comparisons
Medium impact · Medium oddsAcute therapies grew in the mid-teens again in Q2 2025. That is strong for a mature area and reflects market share gains after industry disruption. The risk is that growth slows as the company laps those benefits in late 2025 and into 2026.
Payer or manufacturer pressure
High impact · Medium oddsOption Care depends on reimbursement for drugs, per diems, and nursing services. If payers push down rates or manufacturers reduce drug spreads, revenue can look healthy while profit dollars weaken. STELARA shows how fast one drug economics change can matter.
Policy and supply chain shocks
Medium impact · Low oddsManagement said tariffs, MFN pricing, and similar policy changes should not have a material financial impact in 2025. That lowers near-term risk, but it does not remove longer-term uncertainty. The 2024 IV solution shortage also showed that a supply shock can slow new patient onboarding.
In one breath
What does Option Care Health do?
Option Care Health provides infusion care outside the hospital, mainly in homes and alternate sites. Patients receive complex therapies with support from pharmacists, nurses, and clinical teams.
How does OPCH make money?
The company is reimbursed by payers for the drug, clinical per diems, and nursing services. Its goal is to deliver the same needed therapy in a lower-cost setting than a hospital.
Why does STELARA matter for OPCH?
STELARA matters because the drug's economics reset created a large gross profit headwind. Management expects the 2025 hit to be near the high end of $60 million to $70 million, with about $20 million already seen in Q2.
What should investors watch next?
The key test is whether OPCH can hit its raised 2025 guidance while absorbing the STELARA drag. Investors should also watch whether acute therapy growth stays strong as comparisons get harder.